The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration and COX-2 expression and survival in patients with transitional cell carcinoma of the urinary bladder

被引:53
作者
Hilmy, M. [1 ]
Campbell, R.
Bartlett, J. M. S.
McNicol, A-M
Underwood, M. A.
McMillan, D. C.
机构
[1] Univ Glasgow, Dept Surg, Royal Infirm, Glasgow G31 2ER, Lanark, Scotland
[2] Univ Glasgow, Royal Infirm, Dept Pathol, Glasgow G31 2ER, Lanark, Scotland
关键词
bladder cancer; Ki-67; C-reactive protein; T-lymphocytes; COX-2; survival;
D O I
10.1038/sj.bjc.6603415
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The relationship between the systemic inflammatory response, tumour proliferative activity, T-lymphocytic infiltration, and COX-2 expression and survival was examined in patients with transitional cell carcinoma of the urinary bladder (n = 103). Sixty-one patients had superficial disease and 42 patients had invasive disease. Cancer-specific survival was shorter in those patients with invasive compared with superficial bladder cancer (P < 0.001). On univariate analysis, stratified by stage, increased Ki-67 labelling index (P < 0.05), increased COX-2 expression (P < 0.05), C-reactive protein (P < 0.05) and adjuvant therapy (P < 0.01) were associated with poorer cancer-specific survival. On multivariate analysis of these significant factors, stratified by stage, only C-reactive protein (HR 2.89, 95% CI 1.42-5.91, P = 0.004) and adjuvant therapy (HR 0.29, 95% CI 0.14-0.62, P = 0.001) were independently associated with poorer cancer-specific survival. These results would suggest that tumour-based factors such as grade, COX-2 expression or T-lymphocytic infiltration are subordinate to systemic factors such as C-reactive protein in determining survival in patients with transitional cell carcinoma of the urinary bladder.
引用
收藏
页码:1234 / 1238
页数:5
相关论文
共 44 条
[11]   Cyclo-oxygenase 2: a pharmacological target for the prevention of cancer [J].
Dannenberg, AJ ;
Altorki, NK ;
Boyle, JO ;
Dang, C ;
Howe, LR ;
Weksler, BB ;
Subbararnaiah, K .
LANCET ONCOLOGY, 2001, 2 (09) :544-551
[12]   Targeting cyclooxygenase-2 in human neoplasia: Rationale and promise [J].
Dannenberg, AJ ;
Subbaramaiah, K .
CANCER CELL, 2003, 4 (06) :431-436
[13]   C-reactive protein - An activator of innate immunity and a modulator of adaptive immunity [J].
Du Clos, TW ;
Mold, C .
IMMUNOLOGIC RESEARCH, 2004, 30 (03) :261-277
[14]   HER2 and COX2 expression in human prostate cancer [J].
Edwards, J ;
Mukherjee, R ;
Munro, AF ;
Wells, AC ;
Almushatat, A ;
Bartlett, JMS .
EUROPEAN JOURNAL OF CANCER, 2004, 40 (01) :50-55
[15]   Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer [J].
Forrest, LM ;
McMillan, DC ;
McArdle, CS ;
Angerson, WJ ;
Dunlop, DJ .
BRITISH JOURNAL OF CANCER, 2003, 89 (06) :1028-1030
[16]   Prognostic markers for bladder cancer:: International consensus panel on bladder tumor markers [J].
Habuchi, T ;
Marberger, M ;
Droller, MJ ;
Hemstreet, GP ;
Grossman, HB ;
Schalken, JA ;
Schmitz-Dräger, BJ ;
Murphy, WM ;
Bono, AV ;
Goebell, P ;
Getzenberg, RH ;
Hautmann, SH ;
Messing, E ;
Fradet, Y ;
Lokeshwar, VB .
UROLOGY, 2005, 66 (6A) :64-74
[17]   The relationship between the systemic inflammatory response and survival in patients with transitional cell carcinoma of the urinary bladder [J].
Hilmy, M ;
Bartlett, JMS ;
Underwood, MA ;
McMillan, DC .
BRITISH JOURNAL OF CANCER, 2005, 92 (04) :625-627
[18]   Significant host- and tumor-related factors for predicting prognosis in patients with esophageal carcinoma [J].
Ikeda, M ;
Natsugoe, S ;
Ueno, S ;
Baba, M ;
Aikou, T .
ANNALS OF SURGERY, 2003, 238 (02) :197-202
[19]   Systemic inflammatory response predicts outcome in patients undergoing resection for ductal adenocarcinoma head of pancreas [J].
Jamieson, NB ;
Glen, P ;
McMillan, DC ;
McKay, CJ ;
Foulis, AK ;
Carter, R ;
Imrie, CW .
BRITISH JOURNAL OF CANCER, 2005, 92 (01) :21-23
[20]   Overexpression of interleukin-6 in human basal cell carcinoma cell lines increases anti-apoptotic activity and tumorigenic potency [J].
Jee, SH ;
Shen, SC ;
Chiu, HC ;
Tsai, WL ;
Kuo, ML .
ONCOGENE, 2001, 20 (02) :198-208